SCIENTIFIC EVIDENCE

18 F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis.

Theranostics

Jiang Y, Zeng Q, Jiang Q, Peng X, Gao J, Wan H, Wang L, Gao Y, Zhou X, Lin D, Feng H, Liang S, Zhou H, Ding J, Ai J, Huang R.

Publication Overview

Key findings, Countstar context, and access to the original paper.

2022

Cancer Research

No items found.

Key Finding

The authors then demonstrated that FGFRi-induced transcriptional downregulation of hexokinase 2 (HK2), a key factor of glucose metabolism and FDG trapping, via mTOR pathway leading to this decrease. The novel association between the molecular mechanism (FGFR/mTOR/HK2 axis) and radiological phenotype ( 18 F-FDG PET uptake) of FGFR-targeted therapy was demonstrated in multiple preclinical models.

Countstar Connection

Countstar (model not specified) measured cell numbers in the study's cell samples during quality assessment in the 2022 Theranostics study.

Stay Connected to

Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.

Meet us online